{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:19:20Z","timestamp":1790518760082,"version":"4.1.0"},"reference-count":122,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Treatment of Gaucher Disease (<jats:styled-content style=\"fixed-case\">GD<\/jats:styled-content>) is now beset with the abundance of therapeutic options for an individual patient, making the choice of therapy complex for both expert and non\u2010expert clinicians. The pathogenesis of all disease manifestations is a gene mutation\u2010driven deficiency of glucocerebrosidase, but the clinical expression and response of each of the clinical manifestations to different therapies can be difficult to predict. Enzyme replacement therapy has been available since 1991 and is well\u2010established, with known efficacy and minimal toxicity. Of interest, the three available enzymes are distinct molecules and were registered as new products, not biosimilars. Oral substrate reduction therapy has undergone a revitalisation with a newly approved agent in this class for which some efficacy and toxicity questions have been raised. Herein we present our approach to the management of <jats:styled-content style=\"fixed-case\">GD<\/jats:styled-content> in the era of choices, including a new algorithm for how to manage a newly diagnosed patient.<\/jats:p>","DOI":"10.1111\/bjh.15402","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T10:29:02Z","timestamp":1527589742000},"page":"467-480","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["How we manage Gaucher Disease in the era of choices"],"prefix":"10.1111","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9151-0337","authenticated-orcid":false,"given":"Shoshana","family":"Revel\u2010Vilk","sequence":"first","affiliation":[{"name":"Gaucher Clinic Shaare Zedek Medical Centre Hadassah\u2010Hebrew University Medical School Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Szer","sequence":"additional","affiliation":[{"name":"Royal Melbourne Hospital and Department of Medicine University of Melbourne Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[{"name":"Department of Haematology Royal Free Hospital London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zimran","sequence":"additional","affiliation":[{"name":"Gaucher Clinic Shaare Zedek Medical Centre Hadassah\u2010Hebrew University Medical School Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12409"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2017.01.018"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2144"},{"key":"e_1_2_10_5_1","first-page":"S20","article-title":"Glucosylsphingosine is a reliable response biomarker in Gaucher disease","volume":"123","author":"Arkadir D.","year":"2018","journal-title":"American Journal of Hematology"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.11.007"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2012.04.018"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2015.09.002"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-012-9527-5"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105233242104"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2013.849003"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23382"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90041-8"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0010021"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.3.646.646"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2005.07.005"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.008"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1089\/rej.2006.9.237"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(65)90743-6"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105417"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.025"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2003.10.007"},{"key":"e_1_2_10_23_1","unstructured":"Canadian Agency for Drugs and Technologies in Health(2017)CADTH Common Drug Review. Clinical Review Report for Eliglustat (Cerdelga). Available at: (accessed May 4 2018)."},{"key":"e_1_2_10_24_1","first-page":"498","article-title":"Spectrum of inherited metabolic disorders in pakistani children presenting at a tertiary care centre","volume":"26","author":"Cheema H.A.","year":"2016","journal-title":"Journal of the College of Physicians and Surgeons Pakistan"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2015.30.4.378"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02161-9"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61841-9"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2005.05.005"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.07.3550"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880010290097143"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:BOLI.0000045756.54006.17"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.04.005"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.07.008"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2011.09.009"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jog.12254"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.08.005"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.08.005"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-5072"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10635"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/537S160a"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000304039.11891.29"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.008078"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.017"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.05.002"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.7196\/SAMJ.2016.v106i6.11002"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23381"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-122-1-199501010-00005"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e31818e2c19"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2010.12.024"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2017.06.003"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008878425167"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1779"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2009.09.006"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23056"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1017\/S026502150524228X"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1177\/1076029615578165"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.028"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.018"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2013.04.005"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.003"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2014.05.007"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168135"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.015"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102192"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.179.4.1790961"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2292020296"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.012393"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuro.2009.06.009"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-140"},{"key":"e_1_2_10_70_1","first-page":"2712","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","volume":"25","author":"Maor G.","year":"2016","journal-title":"Human Molecular Genetics"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.08.002"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.11.014"},{"key":"e_1_2_10_73_1","first-page":"541","article-title":"Successful treatment of bone marrow failure in Gaucher's disease with low\u2010dose modified glucocerebrosidase","volume":"83","author":"Mistry P.K.","year":"1992","journal-title":"The Quarterly Journal of Medicine"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20908"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.459"},{"key":"e_1_2_10_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2016.11.006"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00448"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199305273282112"},{"key":"e_1_2_10_79_1","article-title":"Patients\u2019 opinions on genetic counseling on the increased risk of Parkinson Disease among Gaucher Disease Carriers","author":"Mulhern M.","year":"2017","journal-title":"Journal of Genetic Counseling"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24491"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.292"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.012"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/89.9.691"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2013.09.002"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2004.07.009"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.08.006"},{"key":"e_1_2_10_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.12.001"},{"key":"e_1_2_10_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2017.01.006"},{"key":"e_1_2_10_89_1","unstructured":"Pharmaceutical Benefits Advisory Committee(2015)Public Summary Document. ELIGLUSTAT oral capsule 100\u00a0mg Cerdelga\u00ae Genzyme. Available at:http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2015-07\/files\/eliglustat-psd-July-2015.pdf. (Accessed May 4 2018)"},{"key":"e_1_2_10_90_1","first-page":"637","article-title":"A possible therapeutic approach to Krabbe's globoid leukodystrophy and the status of cerebroside synthesis in the disorder","volume":"3","author":"Radin N.S.","year":"1972","journal-title":"Research Communications in Chemical Pathology and Pharmacology"},{"key":"e_1_2_10_91_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0483-x"},{"key":"e_1_2_10_92_1","first-page":"1","article-title":"Risk factors for osteonecrosis in patients with type 1 Gaucher's disease","volume":"20","author":"Rodrigue S.W.","year":"1999","journal-title":"Clinical Orthopaedics and Related Research"},{"key":"e_1_2_10_93_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079732"},{"key":"e_1_2_10_94_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi240"},{"key":"e_1_2_10_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(15)50443-X"},{"key":"e_1_2_10_96_1","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1182\/blood.V110.11.3200.3200","article-title":"Immune thrombocytopenia in Type I Gaucher Disease","volume":"110","author":"Rosenbaum H.","year":"2007","journal-title":"Blood"},{"key":"e_1_2_10_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2010.10.006"},{"key":"e_1_2_10_98_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.96.4.629"},{"key":"e_1_2_10_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010324.pub2"},{"key":"e_1_2_10_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21491"},{"key":"e_1_2_10_101_1","doi-asserted-by":"publisher","DOI":"10.2217\/ebo.12.193"},{"key":"e_1_2_10_102_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010324.pub2"},{"key":"e_1_2_10_103_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901281"},{"key":"e_1_2_10_104_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181928f6a"},{"key":"e_1_2_10_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08613.x"},{"key":"e_1_2_10_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2012.12.002"},{"key":"e_1_2_10_107_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-013-0368-x"},{"key":"e_1_2_10_108_1","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20130081"},{"key":"e_1_2_10_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/8904_2016_548"},{"key":"e_1_2_10_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.002"},{"key":"e_1_2_10_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-308890"},{"key":"e_1_2_10_112_1","volume-title":"Williams\u2019 Hematology","author":"Zimran A.","year":"2016"},{"key":"e_1_2_10_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2017.08.016"},{"key":"e_1_2_10_114_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.4.1107.1107"},{"key":"e_1_2_10_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21369"},{"key":"e_1_2_10_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268649"},{"key":"e_1_2_10_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-366955"},{"key":"e_1_2_10_118_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2012.09.006"},{"key":"e_1_2_10_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.07.002"},{"key":"e_1_2_10_120_1","first-page":"2101","article-title":"Reduction in intravenous infusion duration of enzyme replacement therapy to ten minutes with velaglucerase alfa in adult patients with Type 1 Gaucher Disease (Abstract)","volume":"130","author":"Zimran A.","year":"2017","journal-title":"Blood"},{"key":"e_1_2_10_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2017.09.003"},{"key":"e_1_2_10_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.007"},{"key":"e_1_2_10_123_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-016-0435-x"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15402","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T18:33:36Z","timestamp":1694889216000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/bjh.15402"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15402","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"2018-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}